Form 8-K/A - Current report: [Amend]
SEC Accession No. 0001798749-24-000039
Filing Date
2024-07-01
Accepted
2024-07-01 16:03:32
Documents
13
Period of Report
2024-06-25
Items
Item 2.05: Cost Associated with Exit or Disposal Activities

Document Format Files

Seq Description Document Type Size
1 8-K/A tmb-20240625x8ka.htm   iXBRL 8-K/A 54032
  Complete submission text file 0001798749-24-000039.txt   179451

Data Files

Seq Description Document Type Size
2 EX-101.SCH tmb-20240625.xsd EX-101.SCH 3122
3 EX-101.LAB tmb-20240625_lab.xml EX-101.LAB 16576
4 EX-101.PRE tmb-20240625_pre.xml EX-101.PRE 10778
15 EXTRACTED XBRL INSTANCE DOCUMENT tmb-20240625x8ka_htm.xml XML 5042
Mailing Address 930 WINTER STREET SUITE M-500 WALTHAM MA 02451
Business Address 930 WINTER STREET SUITE M-500 WALTHAM MA 02451 617-443-2400
Aerovate Therapeutics, Inc. (Filer) CIK: 0001798749 (see all company filings)

EIN.: 831377888 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K/A | Act: 34 | File No.: 001-40544 | Film No.: 241090461
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)